What conservative treatment is actually trying to achieve

Every conversation about treating hip osteoarthritis is easier when one fact is established early: the cartilage lost to arthritis does not grow back. Conservative treatment — physiotherapy, anti-inflammatory medication, weight management, intra-articular injections — cannot undo structural damage. What it can do is manage the symptoms that damage produces, slow the rate at which things worsen, and preserve enough function to keep daily life manageable while the right moment for surgery becomes clear.

Those are genuinely worthwhile goals. For many patients they translate into months, sometimes years, of meaningful relief. A structured exercise programme, the right analgesia, or a well-timed injection can make a real difference — not because they address the underlying biology, but because hip osteoarthritis is a condition of varying pace, and a quieter period buys time to plan carefully rather than act under pressure.

The difficulty arises when 'buying time' quietly becomes 'avoiding a decision.' Conservative care works within defined biological limits, and once pain is disrupting sleep, basic tasks are becoming impossible, or X-rays confirm bone-on-bone contact, continuing the same approach is not the cautious choice — it is simply a delayed one.

Which approaches have the strongest evidence

Not all conservative treatments for hip osteoarthritis carry equal weight — and for patients who have spent time managing knee problems, some of the differences are surprising.

What the evidence supports

Pharmacologically, NSAIDs (such as ibuprofen or naproxen, where medically safe) and corticosteroid injections are the most consistently recommended options. OARSI, ACR, EULAR, and AAOS all endorse them for hip OA; they are first-line, not a fallback. Paracetamol and tramadol offer modest short-term pain relief in some patients, but the evidence behind them is considerably weaker, and typical opioids are not recommended for hip OA management.

On the exercise side, the evidence is now robust enough that a 2023 systematic review (Teirlinck et al., PMC9932106, cited 39 times) concluded further trials are unlikely to change the conclusion: structured exercise benefits both pain and physical function. Programmes should run for at least 12 weeks, with twice-weekly supervised sessions complemented by home exercise — the GLA:D model. The focus falls on hip abductor strengthening, core stability, and balance rather than general activity alone.

Several non-pharmacological measures also have meaningful value. Weight management reduces compressive load on the joint and appears in both NHS England and North Yorkshire CCG decision-support pathways as a prerequisite before replacement is considered. A walking cane used in the hand opposite the painful hip can reduce mechanical load on the joint by up to 40% — a simple, immediately available aid. Shock-absorbing footwear rounds out the adjuncts worth adopting early.

What the evidence does not support — for the hip

Glucosamines and viscosupplementation (hyaluronic acid injections) are actively recommended against by most major orthopaedic and rheumatology societies for hip OA. This diverges from knee guidance, where HA in particular occupies a greyer area, and catches many patients off-guard. The hip joint's anatomy and mechanics mean that findings from knee trials do not transfer reliably — a distinction worth understanding before choosing a treatment based on what helped a knee.

Where biologicals and injectables sit in the picture

Biological injectables — micro-fragmented fat, platelet-rich plasma (PRP), and similar preparations — occupy a distinct middle tier in the hip OA treatment sequence: beyond standard first-line care, but short of surgery. For a carefully selected patient with moderate structural damage who wants to defer an operation while their circumstances allow, they represent a reasonable option to discuss with a specialist.

The honest limitation is that most high-quality evidence for these preparations comes from knee studies. Hip-specific data, particularly for PRP, remains incomplete — and as of 2025, no major orthopaedic or rheumatology society formally endorses them for hip OA. That gap reflects where the research currently stands rather than proof of ineffectiveness, but it does mean patients are working with thinner evidence than they might assume.

Micro-fragmented fat injections have shown some success in delaying surgery for the right candidate: typically someone whose pain is not yet severe enough to make replacement the obvious next step, and whose imaging shows change but not complete structural collapse. What biological options cannot do is substitute for surgery once damage is advanced. At that point, continuing to inject rather than act is deferral, not treatment — and the distinction matters.

The decision to pursue a biological injectable is best made within a full clinical assessment of where the joint actually stands. It is one part of a broader conversation about timing and candidacy, not a standalone strategy for avoiding surgery indefinitely.

The signals that suggest conservative care has reached its ceiling

Knowing when to shift the conversation is often the hardest part. Most patients arrive at this point gradually — and the signals, once named, tend to be recognisable.

Night pain and rest pain are among the most telling. When discomfort persists without weight-bearing or movement — waking someone at 3am, or settling in at the end of an evening on the sofa — it indicates the joint is inflamed beyond what loading explains. Pain that loads the joint is one thing; pain at rest is a different category, and one that clinicians treat as a meaningful escalation marker.

Functional thresholds matter just as much. A reduced walking distance that now shapes daily decisions, difficulty managing stairs, and — commonly reported — the inability to dress without real difficulty or discomfort are not merely inconveniences. They represent a measurable loss of independence that conservative care, at that stage, is no longer reversing.

Radiologically, bone-on-bone contact — the complete loss of cartilage space visible on plain X-ray — confirms that structural reserve has been exhausted. It is important to understand this as confirmation rather than the sole trigger: some patients with severe imaging findings are managing adequately, and others with moderate changes are significantly disabled. The X-ray provides evidence; it does not make the decision alone.

NHS guidance places the surgical conversation after a minimum of 3–6 months of genuinely attempted conservative management, but this is a starting point rather than a rigid protocol. What carries equal or greater weight is how the patient reports their quality of life and function — whether the hip is limiting them in ways that matter. For patients whose pain or loss of function has crossed that line, a specialist assessment is a reasonable and timely next step rather than a concession.

Why prolonged delay beyond that point rarely improves outcomes

There is a widely held assumption that waiting longer is the more cautious choice — that delay preserves options. Once structural damage is advanced, clinical experience points in the opposite direction.

The body does not stand still while a decision is being postponed. Persistent pain restricts movement; restricted movement leads to muscle atrophy around the hip and reduced cardiovascular fitness; declining fitness affects how well any patient tolerates and recovers from an eventual operation. Bone quality, too, can deteriorate with prolonged inactivity. None of these changes improve surgical outcomes — and some actively complicate them.

Timely hip replacement, when the indication is clear, carries one of the strongest functional outcome records in elective surgery. Most patients describe the result as a 'forgotten joint' — meaning the hip recedes from conscious attention in daily life, which is precisely what a healthy joint does. That outcome is not diminished by acting when the signal is clear rather than waiting until function has further declined.

On longevity, approximately 58% of total hip replacements are estimated to last at least 25 years, and with the right indication and preparation, implants can perform well beyond 20 years in suitable patients. Framing timely surgery as a loss of something that might have lasted longer is, in that context, clinically inaccurate.

The goal was never to delay surgery as long as possible. It was always to time it well — which is a matter of sound specialist judgement applied to the individual, not a fixed waiting period applied universally.

What the surgical pathway looks like when the time is right

When the decision to proceed is made, what follows is a planned sequence rather than a single event. For selected patients, that sequence begins with a pre-operative assessment — reviewing imaging, general health, and anatomy — before any surgical planning takes place. Implant choice, anaesthetic approach, and the specific technique used all influence how quickly and confidently someone mobilises afterwards.

The SPAIRE approach (Saves Piriformis And Obturator Internus with Repair of Obturator Externus) addresses one of the main vulnerabilities of a posterior hip replacement: disruption to the soft tissues that hold the joint stable. By preserving these tendons rather than dividing them, the technique is designed to reduce dislocation risk and support earlier weight-bearing. For many patients within this pathway, standing and walking with assistance within hours of surgery — rather than days — is a realistic expectation, though the pace depends on individual anatomy and recovery.

The biological rapid recovery programme builds on this surgical foundation by integrating implant selection, post-operative mobilisation protocols, and discharge planning as a single designed pathway rather than a series of separate decisions. For suitable patients, same-day or next-day discharge may be achievable — not as an efficiency measure, but because earlier mobilisation, when the technique supports it, is associated with better recovery trajectories.

Professor Paul Lee, who trained at the internationally recognised Exeter Hip Unit and holds senior consultant roles at the Royal London Hospital and United Lincolnshire Hospitals NHS Trust, brings a particular perspective to this: his 2018 published work on non-pharmacological and non-surgical hip pain management establishes that this surgical approach is built on a thorough understanding of when not to operate. That context changes the weight of the recommendation when surgery is indicated.

A hip replacement planned this way is not the beginning of a long recovery. For many patients, it is the end of one.

1. [1] Hip replacement – NHS. https://www.nhs.uk/conditions/hip-replacement/ https://www.nhs.uk/conditions/hip-replacement/